Clinical trials: Clozapine Resistant Schizophrenia
Clozapine Resistant Schizophrenia
Vitamin D for Schizophrenia
Background: Despite improvements in medications, treatment delivery and rehabilitation, schizophrenia outcomes remain suboptimal. There are a proportion of 30-40% treatment-resistant schizophrenia patients.
- Trial name
- NCT01759485
- Testing
- Vitamin D3
- Where
- Israel
- Volunteers
- 47 people
- Sponsor
- Geha Mental Health Center
Schizophrenia
DAAOI-1 Treatment for Treatment-resistant Schizophrenia
Pharmacotherapy for schizophrenia has limitations such as residual positive and negative symptoms, cognitive deficits and intolerable side effects.
- Trial name
- NCT01390376
- Testing
- DAAOI-1
- Where
- Taiwan
- Volunteers
- 60 people
- Sponsor
- China Medical University Hospital
Schizophrenia, Schizoaffective Disorder
Polypharmacy in Clozapine-resistant Schizophrenia
The aim of this randomized, double-blind study is to verify the hypothesis that clozapine monotherapy is as efficient as a combination of clozapine and olanzapine therapy in treatment-resistant schizophrenia.
- Trial name
- CLOZANS (NCT00918021)
- Testing
- olanzapine
- Where
- Finland
- Volunteers
- 30 people
- Sponsor
- Niuvanniemi Hospital
Psychosis, Intellectual Disability
Study to Compare Clozapine vs Treatment as Usual in People With Intellectual Disability & Treatment-resistant Psychosis
This clinical trial will prove whether a large number of people with intellectual disability and treatment-resistant psychosis could benefit from the use of clozapine.
- Trial name
- CLOZ-AID (NCT04529226)
- Testing
- Clozapine, haloperidol, pimozide, olanzapine, risperidone, amisulpride
- Where
- 20 sites in Spain
- Volunteers
- 75 people
- Sponsor
- Fundación Pública Andaluza para la gestión de la Investigación en Sevilla
Schizophrenia, Schizoaffective Disorder
Minocycline Augmentation to Clozapine
The proposed pilot study will compare minocycline augmentation with clozapine in individuals with high vs low inflammation as measured by CRP.
- Trial name
- NCT02124811
- Testing
- Minocycline
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Emory University
Treatment Resistant Psychosis, Psychosis
Stratification and Treatment in Early Psychosis Study -ASSIST
The purpose of this trial is: To investigate whether the response to clozapine treatment can be enhanced by adding cannabidiol (CBD), compared to placebo, in treatment resistant psychosis patients.
- Trial name
- STEP-ASSIST (NCT07326124)
- Testing
- CBD 100 mg/mL Oral Solution, Placeb
- Where
- 15 sites in Germany, Greece and 6 more
- Volunteers
- 250 people
- Sponsor
- University of Oxford
Bipolar Affective Disorder, Schizoaffective Disorder
Specialized Clozapine Clinic for Bipolar and Schizoaffective Disorder
Bipolar Disorder (BD) and Schizoaffective Disorder (SA) clients. determine if after 12 months of treatment with clozapine, the BMI changes with clients who are councelled as usual regarding weight gain while on Clozapine.
- Trial name
- NCT00683709
- Testing
- Counselling as Usual, CBT
- Where
- Canada
- Volunteers
- 48 people
- Sponsor
- St. Joseph's Healthcare Hamilton
Schizophrenia, Schizoaffective Disorder
Electroconvulsive Therapy in Clozapine-resistant Schizophrenia
Electroconvulsive therapy (ECT) is one of the oldest neuromodulation treatments still used in psychiatry. Only case reports and open label non-randomized studies have been published of ECT in clozapine-resistant schizophrenia…
- Trial name
- NCT02159001
- Testing
- electroconvulsive therapy
- Where
- Finland
- Volunteers
- 20 people
- Sponsor
- Niuvanniemi Hospital
Schizophrenia
Rosiglitazone for Clozapine Induced Glucose Metabolism Impairment
We propose an eight-week, double-blind, placebo-controlled trial of rosiglitazone in schizophrenia subjects treated with clozapine using Bergman's Minimal Model (MINMOD) intravenous glucose tolerance test.
- Trial name
- NCT00337350
- Testing
- rosiglitazone
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Massachusetts General Hospital
Schizophrenia
Response to Clozapine in Treatment Resistant Schizophrenia: A Longitudinal Magnetic Resonance Spectroscopy Study
The purpose of this study is to investigate the relationship between glutamate and related brain chemicals and treatment response to clozapine in patients with treatment-resistant schizophrenia.
- Trial name
- NCT02714894
- Testing
- Clozapine
- Where
- Canada
- Volunteers
- 108 people, healthy volunteers welcome
- Sponsor
- Centre for Addiction and Mental Health
Schizophrenia, Treatment-resistant Schizophrenia
Neural Biomarkers of Clozapine Response
Clozapine has consistently shown to be a superior drug for psychosis in patients who do not respond to other treatments, but its mechanism of action remains unknown.
- Conditions
- Schizophrenia, Treatment-resistant Schizophrenia, Schizoaffective Disorder
- Trial name
- NCT03076346
- Where
- United States
- Volunteers
- 41 people
- Sponsor
- University of Pittsburgh
Schizophrenia
Augmenting Clozapine With Sertindole - SERCLOZ
The purpose of the study is to determine whether addition of sertindole to clozapine treatment can improve psychosis or the metabolic side-effects of clozapine in patients with treatment-resistant schizophrenia.
- Trial name
- NCT00345982
- Testing
- Serdolect
- Where
- Denmark
- Volunteers
- 50 people
- Sponsor
- University of Aarhus
Weight Gain, Sialorrhea
FazaClo Outcomes in the Control of Schizophrenia (FOCUS) Study Survey
AZUR Pharma has received several reports from practicing psychiatrists prescribing FazaClo showing that FazaClo patients start losing body weight instead of keep gaining it, after being switched from other clozapine products or…
- Trial name
- FOCUS (NCT00683891)
- Testing
- FazaClo (clozapine, USP) ODT
- Where
- 2 sites in United States
- Sponsor
- Azur Pharma, Inc
Schizophrenia and Related Disorders, Early Treatment-Resistance
The Effect of a Six Week Intensified Pharmacological Treatment for Schizophrenia Compared to Treatment as Usual in Subjects Who Had a First-time Treatment Failure on Their First-line Treatment.
Schizophrenia (SZ) affects approximately 4.5 million people across the European Union (EU) and is associated with annual healthcare and societal costs of 29 billion Euros.
- Trial name
- INTENSIFY SZ (NCT05958875)
- Testing
- Clozapine, Second-line Antipsychotics (treatment as usual)
- Where
- 13 sites in Austria, Germany and 3 more
- Volunteers
- 418 people
- Sponsor
- Dr. Inge Winter
Sialorrhea
Clozapine-induced Hypersalivation - Feasibility Trial
A randomised placebo-controlled feasibility study of glycopyrrolate and hyoscine in the treatment of clozapine-induced hypersalivation to assess recruitment and retention rates in a multi-centre trial.
- Trial name
- GOTHIC1 (NCT02613494)
- Testing
- Hyoscine, Glycopyrrolate
- Where
- 2 sites in United Kingdom
- Volunteers
- 29 people
- Sponsor
- Mersey Care NHS Trust
Refractory Schizophrenia, Super Refractory Schizophrenia
Electroconvulsive Therapy (ECT) in Patients With Super Refractory Schizophrenia
Introduction: In spite of recent advances in schizophrenia treatment, 30% of patients still do not respond properly to antipsychotic therapy.
- Trial name
- SSURECT (NCT02049021)
- Testing
- MECTA SPECTRUM 5000Q ECT
- Where
- Brazil
- Volunteers
- 20 people
- Sponsor
- University of Sao Paulo
Schizophrenia, Treatment Resistant Schizophrenia
Maintenance ElectroConvulsive Therapy in Clozapine RESISTant Schizophrenia - the MECT-RESIST Trial
Schizophrenia is one of the most severe and costliest mental disorders in terms of human suffering and societal expenditure. About 15-30% of patients do not respond to all known antipsychotics, including clozapine, the current…
- Trial name
- MECT-RESIST (NCT06456983)
- Testing
- maintenance electroconvulsive therapy (mECT)
- Where
- 14 sites in Germany
- Volunteers
- 140 people
- Sponsor
- Central Institute of Mental Health, Mannheim
Schizophrenia, Schizoaffective Disorder
Minocycline Augmentation of Clozapine for Treatment Resistant Schizophrenia
This a randomized double-blind placebo controlled trial which aims to determine the beneficial effects of minocycline augmentation to clozapine in partial responders to Treatment Resistant Schizophrenia (TRS).
- Conditions
- Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder
- Trial name
- NCT02533232
- Testing
- Minocycline
- Where
- 4 sites in Pakistan
- Volunteers
- 60 people
- Sponsor
- Pakistan Institute of Living and Learning
Schizophrenia, Treatment Resistant Disorders
Clozapine Versus Amisulpride in Treatment-resistant Schizophrenia Patients
Background: schizophrenia is a debilitating mental disorder affecting about 1% of the general population. About 30% of patients will not react to current drug treatment and defined as treatment-resistant schizophrenia patients…
- Trial name
- ClozAmi (NCT01448499)
- Testing
- Clozapine, Amisulpride, Clozapine+Amisulpride
- Where
- Israel
- Sponsor
- Geha Mental Health Center
Schizophrenia
Treatment Strategy for Refractory Schizophrenia: Drug Interaction Between Clozapine and Fluvoxamine
Clozapine has been virtually the only psychopharmacological choice in patients with schizophrenia who either did not response to typical neuroleptics or experienced severe extrapyramidal side effects and consequently did not…
- Trial name
- NCT01401491
- Testing
- clozapine plus fluvoxamine
- Where
- Taiwan
- Volunteers
- 80 people
- Sponsor
- Taipei Medical University Hospital